Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Christopher Benton speaks to ecancer in online video interview about the management and treatment of patients with acute lymphoblastic leukaemia (ALL) during the COVID-19 pandemic.
He highlights the main treatment approaches for these patients, and believes they should be managed according to their stage of treatment. These include newly-diagnosed patients on intensive therapy, patients on maintenance therapy, and those who have completed treatment.
Dr Benton also discusses the role of telemedicine, which has been heavily utilised during the course of the pandemic.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma In Rwanda: The need for further research
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Synthetic biology and precision medicine in blood and gynaecological cancers
OncoAlert Round Up for August 25th - 31st, 2023
ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC
Choosing wisely in multiple myeloma